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Abstract
Background: In the US, the approved multiple sclerosis (MS) oral disease-modifying therapies (ODMTs) are
fingolimod (FTY), teriflunomide (TFN), and dimethyl fumarate (DMF). FTY and TFN are recommended with
once-daily doses with no up-titration, whereas DMF treatment is recommended twice-daily (BID) and is initiated
with a 7-day starter dose of 120 mg BID before up-titration to the maintenance dose of 240 mg BID. Limited
information exists regarding real-world ODMT prescribing patterns to aid physician/patient decision-making.
Methods: Eligible patients for this retrospective medical record review were ≥18 years, had one visit related to
ODMT initiation (index visit), and ≥1 visit within 12 months before and after the index visit. Primary objectives were
to assess post-index ODMT persistency (i.e., discontinuation), prescribing patterns (medication switching, dose up-
titrations, dose reduction, re-starts, and add-ons) and medical resource utilization (office-visits, MRI procedures, and
mobility indicators) at distinct time windows of 3, 6, 9, and 12 months. Chi-square or Wilcoxon Rank Sum tests were
used for 3-way ODMT group comparisons.
Results: Medical records of 293 MS-diagnosed patients using ODMTs were abstracted from 19 US-based neurology
clinics between December 31, 2010 and June 30, 2014 (FTY: 101; DMF: 133; TFN: 59). Persistency rates among
ODMT groups were similar. MS-related medication switching, dose reduction, re-starts, and add-ons were
infrequently observed and were similar across ODMT groups. Of DMF patients with a confirmed starting dose of
120 mg BID with ≥12 months follow-up (n = 26), the percentage who were prescribed dose up-titrations to the
recommended maintenance DMF dose was 23.1 % at 1–3 months, 26.9 % at 4–6 months, 42.3 % at 7–9 months,
and 0 % at 10–12 months. There were no significant differences at any time window among the ODMT groups in
the number of office visits or percent of patients receiving MRIs. Mobility indicator patterns (proportion of patients
with abnormal gait, wheelchair use, etc.) were consistent over time.
Conclusions: There was no difference in persistency, prescribing patterns (medication switching, dose reduction,
re-starts, and add-ons) or medical resource utilization (office-visits, MRI procedures, and mobility indicators) among the
ODMTs. However, in a small sub-group of patients, delays of up to 9 months in DMF dose-up titration to the
recommended maintenance dose were observed.
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Background
Disease modifying therapies (DMTs) in relapsing-
remitting multiple sclerosis (RRMS) have been shown
to prevent relapses and reduce the magnetic reson-
ance imaging (MRI)-apparent lesions that are indica-
tive of MS activity [1]. Until 2010, only injectable
DMTs were available for patients with RRMS. The
proportion of patients adherent to injectable DMTs
ranges from approximately 55 to 90 % [2, 3] and per-
sistence after 1 year is approximately 50 % [4]. In a
systematic review of observational and randomized,
controlled trials of injectable DMTs, the most-cited
reasons for discontinuing therapy were adverse events
and lack of efficacy [5]. Furthermore, data from the
review revealed a high incidence of flu-like symptoms
and injection site reactions that persisted over time.
Such tolerability issues have been shown to directly
impact persistence and adherence [6, 7].
As of 2015, three oral DMTs (ODMTs) [i.e., fingoli-
mod (FTY), teriflunomide (TFN), and dimethyl fumarate
(DMF)] have become available in many countries, in-
cluding the US, as an alternative to injectable DMTs. In
randomized, double-blind, placebo-controlled trials FTY,
TFN, and DMF significantly reduced the annualized re-
lapse rate and the occurrence of MRI lesions when com-
pared with placebo [8–10].
The three ODMTs differ in how they are dosed in pa-
tients with RRMS. DMF is available as a starter dose
(120 mg twice daily [BID]) and a maintenance dose
(240 mg BID), with the dose titration to 240 mg BID
recommended after the first 7 days of use [11]. For pa-
tients who do not tolerate the DMF maintenance dose,
temporary dose reductions to 120 mg BID may be con-
sidered, but the full maintenance dose should be re-
sumed within 4 weeks. In contrast, FTY is only available
in one dose (0.5 mg), and TFN is available in two doses
(14 mg and 7 mg); neither have starter doses in their
regimens [12, 13]. DMF is taken twice a day (both
starter dose and maintenance dose), whereas FTY and
TFN are taken once a day. Only patients taking FTY are
required to have a first dose observation involving a
baseline electrocardiogram (ECG) and a ≥6 h observa-
tion period.
Given the availability of multiple DMTs, and that sev-
eral ODMTs are relatively new to the US market, infor-
mation regarding real-world ODMT prescribing patterns
is important for appropriate prescribing of these agents.
Information on the characteristics and healthcare use of
patients receiving each ODMT could provide clues as to
prescriber-perceived efficacy and safety of ODMTs, as
well as provide basic information on healthcare resource
burden. Thus, the primary objective of this analysis was
to describe the MS-related medication persistency, pre-
scribing patterns, and concomitant medical resource
utilization of patients with MS receiving ODMTs in the
US. Secondary objectives were to describe the demo-




In this retrospective medical record abstraction study, a
sample of MS patients was drawn from a target goal of
25 specialty neurology practices. The practices were pre-
identified as high prescribers (≥10 prescriptions from
March 2013 to March 2014) of ODMT agents using data
obtained from IMS Health. In order to reflect US disease
prevalence and treatment patterns, geographic distribu-
tion of site selection in this study was modelled accord-
ing to US region per the distribution of prescribers
observed in the IMS Health data, such that if 50 % of
prescribers were in the South according to the IMS
Health data, 50 % of the study sample’s prescribers en-
rolled for this study were from the South. The goal was
250 medical charts in a 2:2:1 ratio for FTY, DMF, and
TFN; the ratio was determined based on market share at
the time of study planning. Physicians at the sites were
asked to contribute charts based on inclusion and exclu-
sion criteria. A minimum of five charts and a maximum
of 15 charts was collected from participating sites.
Charts were non-randomly reviewed on a first-served
basis until the quota of charts was reached for each
drug. A request was submitted and granted by the
reviewing institutional review board waiving the require-
ment for patient informed consent; approval to conduct
the study was obtained from a centralized institutional
review board (Sterling IRB; Atlanta, GA).
An identification period from December 31, 2011 to
December 31, 2013 was used to identify the first record
of use of an ODMT (index date) via prescription or
chart notation. The total observation period of the study
was from December 31, 2010 to June 30, 2014. Eligible
patients were ≥18 years of age on the index date, had at
least one record of a physician-prescribed ODMT during
the identification period of the study, had at least one
visit to the site neurology practice in the 12 months be-
fore the index date (pre-index period, baseline visit; any-
time between December 31, 2010 and December 31,
2012), and had at least one additional site visit in the
post-index period (in addition to the index date visit;
anytime between December 31, 2012 and June 30, 2014).
Patients with missing documentation of MS diagnosis or
missing information on sex and/or age in their medical
record were excluded from the study.
Record abstraction process
The abstractors used in this study were nurses or phar-
macists with previous experience abstracting
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information from neurology or MS patient records. To
help ensure consistency of data collection, the abstrac-
tors were trained on the study design and presented with
standardized data collection forms and a detailed code-
book which contained definitions of the target variables.
They were also trained on mandatory safety reporting
procedures as required by the study sponsor.
Upon completion of the data collection process, a
quality control assessment was completed by study in-
vestigators to ensure adequate data capture and quality.
Each abstractor’s responses underwent an inter-rater re-
liability check to ensure consistency.
De-identified data were captured on a paper optical
character recognition form that was scanned into a
Microsoft Access database. From there, it was imported
into SAS version 9.2 and checked for appropriate values
using logic and range checks by the record abstraction
research manager.
Information collected from medical records
Information collected during the study period from each
record included demographics, clinical characteristics
(i.e., MS diagnosis, year of diagnosis, comorbidities, MS
symptoms, etc.), ODMT prescriptions, symptomatic
medication prescriptions, and medical resource utilization.
Information was collected on ODMT persistency (propor-
tion of patients discontinuing treatment) and prescribing
patterns in the post-index period based on a review of
doses, and/or physician narratives; patterns assessed in-
cluded dose titration to recommended maintenance doses,
dose reductions, switching to another MS DMT, re-starts
(re-initiation of index ODMT ≥30 days after discontinu-
ation), and add-ons (treatment with additional MS DMTs
with no indication the index ODMT was discontinued).
Post-index medical resource utilization was also extracted,
including the number of outpatient office visits and MRI
procedures. Notations of mobility indicators (abnormal
gait, dizzy gait, walk trials [e.g., timed 25-ft walk trial],
wheelchair use, and crutch/cane/walker use) were tracked
post-index. An additional excel file shows the raw data
collected in detail (see Additional file 1).
Data analysis
All post-index abstracted information was explored in a
cumulative fashion at distinct time windows of 3, 6, 9,
and 12 months. Patients had variable enrollment lengths;
thus, the patient sample size was different for each post-
index time period (Table 1). An additional analysis for
dose titration to recommended maintenance doses for
DMF was conducted among the subset of DMF patients
who had a confirmed starting dose of 120 mg BID. Fur-
thermore, dose titration analyses were conducted at each
post-index time period using only the subset of patients
with a follow-up of at least 9 or 12 months to gain longi-
tudinal insight into observed up-titrations.
Both descriptive and univariate statistical analyses de-
signed to compare pre-index (baseline), index, and post-
index abstracted variables between the ODMT patient
cohorts were conducted. Only reported values were ana-
lyzed; no imputation was made for missing data since it
was not possible to determine if a missing observation
was due to no information or an oversight in recording.
All categorical variables were reported as raw counts or
percentages and were analyzed using Chi-square tests.
For the Chi-square tests, test results were deemed ‘inde-
terminant’ when 50 % of more of the cells compared
had less than five observations. Continuous variables
were analyzed using the non-parametric Wilcoxon Rank
Sum test. Two sided p-values <0.05 denoting statistical
significance were reported where applicable. All analyses
were conducted using SAS version 9.3 statistical soft-
ware (Cary, NC).
Results
Patient demographics and clinical characteristics
Medical records of 293 MS-diagnosed patients using
ODMTs were abstracted from 19 US-based neurology
clinics between December 31, 2010 and June 30, 2014
Table 1 Patient followed up/follow-up information
Total FTY DMF TFN P-value
(3 groups)(N = 293) (N = 101) (N = 133) (N = 59)
Index date, (SD) 7/11/2013 (180 days) 6/6/2013 (235 days) 8/15/2013a (128 days) 6/29/2013 (159 days) 0.0370
Enrollment end date, (SD) 7/4/2014 (17 days) 7/5/2014 (17 days) 7/3/2014 (16 days) 7/5/2014 (20 days) 0.1326
Mean follow-up duration, days (SD) 357.6 (176.5) 393.5 (229.8) 323.0 (123.6) 371.3 (156.9) 0.0300
Patients enrolled at least X months, n (%)
3 months 281 (95.9) 98 (97.0) 124 (93.2) 59 (100) 0.0720
6 months 236 (80.5) 79 (78.2) 106 (79.7) 51 (86.4) 0.4235
9 months 188 (64.2) 63 (62.3) 85 (63.9) 40 (67.8) 0.7856
12 months 151 (51.5) 55 (54.5) 65 (48.9) 31 (52.5) 0.6885
DMF dimethyl fumarate, FTY fingolimod, TFN teriflunomide
an = 128
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(Fig. 1). Of the 293 records, 101 were for FTY, 133 were
for DMF, and 59 were for TFN. The patients prescribed
FTY were younger than the DMF and TFN patients
(mean ± SD; 44.2 ± 10.7 years vs 49.6 ± 10.3 years vs 50.6
± 9.6 years, respectively; 3-way comparison P < 0.0001;
Table 2), and had a longer period of follow-up
(393.5 days vs 323.0 days vs 371.3 days, respectively; 3-
way comparison P = 0.0300; Table 1). There was a sig-
nificant difference in the regional distribution of patients
with prescriptions for ODMTs in this study sample (3-
way comparison P < 0.0001). A large proportion of pa-
tients prescribed FTY and TFN resided in the South
(>40 %), whereas only 1 % of the patients prescribed
FTY resided in the West (Table 2).
The vast majority of comorbidities pre-specified for
examination in the study, such as heart disease, asthma,
stroke, arthralgia, etc., were not observed in medical re-
cords (documented in less than 2 % of patients); there-
fore, statistical analysis was limited to depression,
diabetes, and hypertension. Patients prescribed FTY had
a lower incidence of reported hypertension compared
with DMF and TFN (3.0 vs 11.3 vs 18.6 %, respectively;
3-way comparison P = 0.00461); however, in general
there did not appear to be any distinct comorbidity pat-
terns across the ODMT patient groups.
At the baseline visit, fatigue and abnormal gait were the
most commonly reported MS symptoms (Fig. 2). The inci-
dence of spasticity, depression, and visual disturbances
was significantly different among the three ODMT patient
groups and was lowest in patients prescribed FTY
when compared with DMF and TFN (3-way
comparison P ≤ 0.05; Fig. 2). In the post-index follow-
up time windows of 3, 6, 9, and 12 months, there
were no consistent patterns in the differences in MS
symptoms among the ODMT patient groups.
At the baseline visit, antidepressants and muscle re-
laxants were the most common symptomatic drug
prescriptions (Fig. 3). The percentage of patients with
muscle relaxant prescriptions was significantly differ-
ent among the three ODMT patient groups, and was
lowest in patients prescribed FTY compared with
DMF and TFN (3-way comparison P = 0.04; Fig. 3). In
the post-index follow-up time windows of 3, 6, 9, and
12 months, symptomatic drug prescriptions were not
often reported.
ODMT persistency and prescribing patterns
In the post-index period, ODMT persistency and prescrib-
ing patterns were tracked at each distinct time window in
a cumulative fashion at 3, 6, 9, and 12 months to assess
change over time (Table 3). Because patients had varying
durations in their time of follow-up, the size of the patient
samples was different for each time window. There was
no significant difference in the persistency rate among the
ODMT patient groups at any time window (Table 3); the
overall rate of discontinuation (%) within 3, 6, 9, and
12 months was 4.3, 7.6, 13.3, and 14.6, respectively. MS-
related medication switching, ODMT dose reduction,
ODMT re-starting, and add-on treatments were observed
infrequently (each outcome identified in a maximum of
4 % of patients within 9 months and 7 % of patients within
12 months), and were similar across the ODMT patient
Fig. 1 Medical record selection process. DMF = dimethyl fumarate; ODMT = oral disease-modifying therapy; FTY = fingolimod; TFN = teriflunomide
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groups. The frequency of dose titrations to recommended
maintenance doses with DMF was assessed at each post-
index time window in patients that had a confirmed start-
ing dose of 120 mg BID. This analysis revealed that by 3,
6, 9, and 12 months, a cumulative total of 26.4, 52.3, 88.9,
and 92.3 % of patients, respectively, had a recorded dose
titration to the recommended maintenance DMF dose
(Fig. 4). A longitudinal analysis tracking DMF patients
with a confirmed starting dose of 120 mg BID, and who
had follow-up durations of at least 9 months (n = 36 of
133 DMF patients) or 12 months (n = 26 of 133 DMF pa-
tients), revealed delays in the dose titration to the
recommended maintenance dose (Fig. 5). The proportion
of DMF patients with ≥9 months follow-up who experi-
enced their first dose titration to the recommended main-
tenance dose was 22.2 % at 1–3 months, 30.6 % at 4–6
months, and 36.1 % at 7–9 months, and in patients with
≥12 months follow-up was 23.1 % at 1–3 months, 26.9 %
at 4–6 months, and 42.3 % at 7–9 months (0 % at 10–12
months).
Medical resource utilization
In the post-index period, there were no significant differ-
ences at any time window among the ODMT patient
Table 2 Demographics of ODMT patients
Total FTY DMF TFN P-value
(3 groups)(N = 293) (N = 101) (N = 133) (N = 59)
Female, n (%) 214 (73.0) 75 (74.3) 96 (72.2) 43 (72.9) 0.9386
Mean age, y (SD) 48.0 (10.7) 44.2 (10.7) 49.6 (10.3) 50.6 (9.6) <0.0001
Age group, n (%) 0.0349
18–24 years 2 (0.7) 2 (2.0) 0 0
25–34 years 33 (11.3) 18 (17.8) 12 (9.1) 3 (5.1)
35–44 years 81 (27.7) 34 (33.7) 32 (24.2) 15 (25.4)
45–54 years 100 (34.3) 31 (30.7) 49 (37.1) 20 (33.9)
55–64 years 59 (20.2) 12 (11.9) 29 (22.0) 18 (30.5)
65–74 years 13 (4.5) 4 (4.0) 7 (5.3) 2 (3.4)
75+ years 4 (1.4) 0 3 (2.3) 1 (1.7)
Missing 1 (0.3) 0 0 0
Region, n (%) <0.0001
Midwest 73 (25.1) 32 (32.3) 37 (27.8) 4 (6.8)
Northeast 58 (19.9) 24 (24.2) 26 (19.6) 8 (13.6)
South 105 (36.1) 42 (42.4) 37 (27.8) 26 (44.1)
West 55 (18.9) 1 (1.0) 33 (24.8) 21 (35.6)
Missing 2 (0.7) 0 0 0
Race, n (%) 0.0074
White 61 (21.1) 29 (28.7) 28 (21.5) 4 (6.9)
Black 11 (3.8) 7 (6.9) 1 (0.8) 3 (5.2)
Other 3 (1.0) 1 (1.0) 1 (0.8) 1 (1.7)
Unknown 214 (74.1) 64 (63.4) 100 (76.9) 50 (86.2)
Missing 4 (1.4) 0 0 0
Insurance, n (%) 0.0051
Commercial 70 (24.1) 15 (15.0) 35 (26.5) 20 (34.5)
Medicaid 8 (2.8) 0 6 (4.6) 2 (3.5)
Medicare 28 (9.7) 4 (4.0) 16 (12.1) 8 (13.8)
Cash 2 (0.7) 1 (1.0) 1 (0.8) 0
Other 5 (1.7) 2 (2.0) 3 (2.3) 0
Unknown 177 (61.0) 78 (78.0) 71 (53.8) 28 (48.3)
Missing 3 (1.0) 0 0 0
DMF dimethyl fumarate, ODMT oral disease-modifying therapy, FTY fingolimod, TFN teriflunomide
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groups in the number of outpatient office visits (range of
2.3 to 2.6 visits within 12 months), or percent of patients
receiving MRIs (range of 32.3 to 49.2 % within
12 months). At the 3-month post-index time window,
the most commonly recorded mobility indicator for all
three ODMT patient groups was abnormal gait (31.0 %);
the least commonly recorded mobility indicator was
wheelchair use (4.6 %). Walking with a crutch/cane/
walker was significantly different among the ODMT
groups, and was highest in patients prescribed TFN
(18.6 %; 3-way comparison P = 0.05). The mobility indi-
cator patterns remained consistent over the 6, 9, and
12 month time windows; however, the statistical differ-
ence for walking with a crutch/cane/walker disappeared,
and there were no other significant differences among
the ODMT patient groups.
Discussion
Analysis of ODMT discontinuations in this study indi-
cated that the persistency rate did not differ among
ODMT patient groups FTY, DMF, and TFN. Reports of
MS-related medication switching, ODMT dose reduc-
tion, ODMT re-starting, and add-on treatments were in-
frequent. Delays in the up-titration to the maintenance
dose of DMF were observed up to 9 months after treat-
ment initiation.
Assessment of medical resource utilization among the
ODMT patient groups revealed no notable differences in
Fig. 2 Incidence of reported multiple sclerosis symptoms at the baseline visit. *P≤ 0.05 for 3-way comparison. DMF = dimethyl fumarate;
FTY = fingolimod; TFN = teriflunomide
Fig. 3 Incidence of reported symptomatic medication use at the baseline visit. Only medication use with an incidence of ≥10 % in any group is reported.
*P= 0.04 for 3-way comparison. DMF = dimethyl fumarate; FTY = fingolimod; NSAID = non-steroidal anti-inflammatory drug; TFN = teriflunomide
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the number of outpatient office visits, MRI procedures, or
mobility patterns. When examining demographics and
clinical characteristics of patients prescribed ODMTs, pa-
tients prescribed FTY were on average younger and had a
longer follow-up period than patients prescribed DMF or
TFN. The comorbidity profile appeared to be similar be-
tween the ODMT cohorts with the exception of hyperten-
sion. The lower incidence of hypertension with FTY may
be due to cautious prescribing to patients with cardiac
conditions per prescribing information.
The lack and/or delay of a recorded dose up-titration
to the maintenance dose observed for many of the pa-
tients prescribed DMF is an important finding within
our examination of real-world ODMT use. Per the FDA
prescribing information, the initial 120 mg BID dose
should be taken for 7 days, followed by dose escalation
to the maintenance 240 mg BID dose [11]. There are no
efficacy data to support use of the 120 mg BID DMF
dose as a maintenance dose [14]. Therefore, it is possible
patients who experience delays up-titrating to the DMF
maintenance dose beyond the recommended 7-day ini-
tial dosing period may be more likely to experience
negative outcomes such as relapses or disease progres-
sion. More research is needed to understand the extent
of delays and the impact of under-dosing patterns asso-
ciated with DMF, as observed in this study.
The reasons for the delay in DMF up-titration are un-
known. One possibility is that DMF is a relatively new
DMT, and cautionary prescribing could result in some
delays in up-titration, although this is unlikely to ac-
count for the length of the delays observed in this study.
Another possibility is a delay due to concerns regarding
gastrointestinal intolerance with the maintenance dose
as observed in clinical trials. In pivotal clinical trials for
DMF, gastrointestinal adverse events (i.e. diarrhea, nau-
sea, upper abdominal pain, vomiting) occurred in a com-
bined total of 42 % of subjects receiving DMF, and a
total of 4 % of subjects discontinued due to gastrointes-
tinal events [8, 15, 16].
Persistence of medication use is a major hurdle for the
treatment of chronic disease. Of the total 151 patients
Table 3 ODMT discontinuation rates at cumulative post-index
time windows of within 3, 6, 9, and 12 months. Because patients
had varying durations in their time of follow-up, sample sizes
were different for each time window. P-values for medication
switching, dose reduction, re-starts, and add-ons were indeterminate,
therefore, these data are not shown
Prescribing
parameters, n (%)
Total FTY DMF TFN P-value
(3 groups)(N = 293) (N = 101) (N = 133) (N = 59)
Within 3 months
Patients, n 281 98 124 59
Discontinuation 12 (4.3) 5 (5.1) 5 (4) 2 (3.4) 0.8629
Within 6 months
Patients, n 236 79 106 51
Discontinuation 18 (7.6) 5 (6.3) 6 (5.7) 7 (13.7) 0.177
Within 9 months
Patients, n 188 63 85 40
Discontinuation 25 (13.3) 6 (9.5) 12 (14.1) 7 (17.5) 0.4866
Within 12 months
Patients, n 151 55 65 31
Discontinuation 22 (14.6) 6 (10.9) 9 (13.8) 7 (22.6) 0.3299
DMF dimethyl fumarate, ODMT oral disease-modifying therapy, FTY fingolimod,
TFN teriflunomide
Fig. 4 Cumulative percentage of patients prescribed DMF who had a confirmed starting dose of 120 mg twice-daily, and who were prescribed a
dose up-titration to the recommended maintenance dose. DMF = dimethyl fumarate
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with 12 months of follow-up in this analysis, the rate of
discontinuation overall with the ODMTs was 14.6 %.
The rates observed in this study were lower than the
discontinuation rates reported in other “real world”
retrospective analyses of ODMTs. However, differences
are expected due to variation in data source and study
design. In one retrospective claims database analysis of
3,750 US MS patients, discontinuation within 1 year of
initiation was 27.9 % for FTY, 39.5 % for glatiramer acet-
ate, 43.7 % for interferon, and 39.0 % for natalizumab
[2]. This FTY discontinuation rate is nearly identical to
that found in another retrospective claims analysis of
1,891 US MS patients in a different database, where the
rate of discontinuation for FTY after 1 year was 27.8 %
[4]. One-year discontinuation rates for DMF and TFN
outside of clinical trials have yet to be investigated; how-
ever, shorter-term analyses have found differences in dis-
continuation among oral DMTs in smaller timeframes.
A single-center analysis of 743 MS patients initiating
FTY or DMF found that the 3-month discontinuation
rates were significantly different at 8 and 16 %, respect-
ively [17]. The results from the current analysis did not
reveal any significant difference in discontinuation rates
among the three ODMTs.
The strength of this analysis is that it is the first to
evaluate real world of all the available ODMTs in one
study with up to a 1-year follow-up time frame. Medical
records provide a unique insight into health care pro-
viders’ view of the MS patient and ODMT as well as
richer clinical detail on patients’ conditions and care.
Chart abstraction studies are known to be subject to
documentation practices and data capture limitations,
which may impact medication prescribing insights as
well as insights into patient characteristics. The MS
symptoms were captured as reported in the medical
charts and were not necessarily defined by specific cri-
teria (e.g., Diagnostic and Statistical Manual of Mental
Disorders to diagnose depression); therefore, symptom
Fig. 5 Timing of first DMF dose titrations to the recommended maintenance dose in patients with a confirmed starting dose of 120 mg twice-daily,
and followed-up for at least a 9 months (n = 36) or b 12 months (n = 26). DMF = dimethyl fumarate
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results must be interpreted with caution. There may also
have been a lag in recording of events, such that the tim-
ing of the prescribing patterns reported here may only
be reflective of the time the events were recorded and
not when the actual events occurred. However, it is very
likely that these prescribing patterns coincided with for-
mal care-seeking behavior, such as office visits. Further-
more, medication utilization as notated in the chart
denotes what the physician prescribed and does not ac-
count for subsequent patient behavior. It is also possible
that patients received medication samples from their
prescribing physician, which may or may not have been
captured in the medical record. Our study represents a
convenience sample and may be subject to participation
bias. Lastly, the length of follow-up was 12 months and
the number of patients with 12-month follow-up data in
every ODMT group was small; replication of the study
with a longer follow-up and more patients may be war-
ranted to examine prescribing patterns, healthcare re-
source utilization and patient types, and determine the
impact on disease progression, relapse rates, and mobil-
ity indicators in MS.
Conclusions
Our medical chart abstraction study found no difference in
prescribing patterns (i.e. discontinuation, medication
switching, dose reduction, re-starts, and add-ons) or med-
ical resource utilization (office-visits, MRI procedures, and
mobility indicators) among the ODMTs. However, in a
small sub-group of patients who started on the 120 mg BID
dose, delays of up to 9 months in DMF dose-up titration to
the recommended maintenance dose were observed. Pa-
tients who experience these delays may be more likely to
experience negative outcomes. Further study with more pa-
tients and longer follow-up is warranted to confirm and
elaborate upon our findings.
Additional file
Additional file 1: Multiple sclerosis patients receiving oral disease-
modifying therapies medical record review. Data file contains multiple-
sclerosis patient medical record reviews. Each row is a distinct patient.
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